Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver disease and hepatocellular carcinoma

Journal of Clinical Medicine

Volumn 5, Issue 3, 2016, Pages

  Afonso, Marta B ^a   Rodrigues, Pedro M ^a   Simão, André L ^a   Castro, Rui E ^a,b  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

Biomarker; Hepatocellular carcinoma; Liver; MicroRNA; Nonalcoholic fatty liver disease; Plasma; Serum

Indexed keywords

ARGONAUTE 2 PROTEIN; GELATINASE B; HIGH DENSITY LIPOPROTEIN; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN; MICRORNA; MICRORNA 10B; MICRORNA 122; MICRORNA 122 5P; MICRORNA 1290; MICRORNA 15B; MICRORNA 16; MICRORNA 181A; MICRORNA 192; MICRORNA 192 5P; MICRORNA 21; MICRORNA 27B 3P; MICRORNA 33A; MICRORNA 33B; MICRORNA 34A; MICRORNA 375; NUCLEOPHOSMIN; PIWI PROTEIN; SIRTUIN 1; SMALL UNTRANSLATED RNA; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

CANCER GROWTH; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; REVIEW; UPREGULATION;

EID: 85048814308     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5030030     Document Type: Review

References (148)

1. Starley, B.Q.; Calcagno, C.J.; Harrison, S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010, 51, 1820-1832. [CrossRef] [PubMed]
2. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2012, 56, 908-943
3. Blachier, M.; Leleu, H.; Peck-Radosavljevic, M.; Valla, D.C.; Roudot-Thoraval, F. The burden of liver disease in Europe: A review of available epidemiological data. J. Hepatol. 2013, 58, 593-608. [CrossRef] [PubMed]
4. Wieckowska, A.; McCullough, A.J.; Feldstein, A.E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future. Hepatology 2007, 46, 582-589. [CrossRef] [PubMed]
5. Angulo, P. GI epidemiology: Nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2007, 25, 883-889. [CrossRef] [PubMed]
6. Mofrad, P.; Contos, M.J.; Haque, M.; Sargeant, C.; Fisher, R.A.; Luketic, V.A.; Sterling, R.K.; Shiffman, M.L.; Stravitz, R.T.; Sanyal, A.J. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37, 1286-1292. [CrossRef] [PubMed]
7. Jelic, S.; Sotiropoulos, G.C.; Group, E.G.W. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, 21 (Suppl. S5), v59-v64. [CrossRef] [PubMed]
8. Kishikawa, T.; Otsuka, M.; Ohno, M.; Yoshikawa, T.; Takata, A.; Koike, K. Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J. Gastroenterol. 2015, 21, 8527-8540. [CrossRef] [PubMed]
9. Wang, J.; Liu, X.; Wu, H.; Ni, P.; Gu, Z.; Qiao, Y.; Chen, N.; Sun, F.; Fan, Q. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010, 38, 5366-5383. [CrossRef] [PubMed]
10. Jalali, S.; Bhartiya, D.; Lalwani, M.K.; Sivasubbu, S.; Scaria, V. Systematic transcriptome wide analysis of lncRNA-miRNA interactions. PLoS ONE 2013, 8, e53823. [CrossRef] [PubMed]
11. Yuan, X.; Wang, J.; Tang, X.; Li, Y.; Xia, P.; Gao, X. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. J. Transl. Med. 2015, 13, 24. [CrossRef] [PubMed]
12. Quagliata, L.; Terracciano, L.M. Liver diseases and long non-coding RNAs: New insight and perspective. Front. Med. 2014, 1, 35. [CrossRef] [PubMed]
13. Yu, F.J.; Zheng, J.J.; Dong, P.H.; Fan, X.M. Long non-coding RNAs and hepatocellular carcinoma. Mol. Clin. Oncol. 2015, 3, 13-17. [CrossRef] [PubMed]
14. Panzitt, K.; Tschernatsch, M.M.; Guelly, C.; Moustafa, T.; Stradner, M.; Strohmaier, H.M.; Buck, C.R.; Denk, H.; Schroeder, R.; Trauner, M., et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007, 132, 330-342. [CrossRef] [PubMed]
15. Iizuka, N.; Oka, M.; Yamada-Okabe, H.; Mori, N.; Tamesa, T.; Okada, T.; Takemoto, N.; Tangoku, A.; Hamada, K.; Nakayama, H., et al. Comparison of gene expression profiles between hepatitis B virus-and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res. 2002, 62, 3939-3944.[PubMed]
16. Yang, F.; Zhang, L.; Huo, X.S.; Yuan, J.H.; Xu, D.; Yuan, S.X.; Zhu, N.; Zhou, W.P.; Yang, G.S.; Wang, Y.Z., et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 2011, 54, 1679-1689. [CrossRef] [PubMed]
17. Lu, J.; Xie, F.; Geng, L.; Shen, W.; Sui, C.; Yang, J. Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV. Tumour Biol. 2015, 36, 3231-3236. [CrossRef] [PubMed]
18. Williams, G.T.; Farzaneh, F. Are snoRNAs and snoRNA host genes new players in cancer? Nat. Rev. Cancer 2012, 12, 84-88. [CrossRef] [PubMed]
19. Chen, W.D.; Zhu, X.F. Small nucleolar RNAs (snoRNAs) as potential non-invasive biomarkers for early cancer detection. Chin. J. Cancer 2013, 32, 99-101. [CrossRef] [PubMed]
20. Liao, J.; Yu, L.; Mei, Y.; Guarnera, M.; Shen, J.; Li, R.; Liu, Z.; Jiang, F. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol. Cancer 2010, 9, 198. [CrossRef] [PubMed]
21. Matera, A.G.; Terns, R.M.; Terns, M.P. Non-coding RNAs: Lessons fromthe small nuclear and small nucleolar RNAs. Nat. Rev. Mol. Cell Biol. 2007, 8, 209-220. [CrossRef] [PubMed]
22. Baraniskin, A.; Nopel-Dunnebacke, S.; Ahrens, M.; Jensen, S.G.; Zollner, H.; Maghnouj, A.; Wos, A.; Mayerle, J.; Munding, J.; Kost, D., et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int. J. Cancer 2013, 132, E48-E57. [CrossRef] [PubMed]
23. Mei, Y.P.; Liao, J.P.; Shen, J.; Yu, L.; Liu, B.L.; Liu, L.; Li, R.Y.; Ji, L.; Dorsey, S.G.; Jiang, Z.R., et al. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene 2012, 31, 2794-2804. [CrossRef] [PubMed]
24. Kuhlmann, J.D.; Baraniskin, A.; Hahn, S.A.; Mosel, F.; Bredemeier, M.; Wimberger, P.; Kimmig, R.; Kasimir-Bauer, S. Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer. Clin. Chem. 2014, 60, 206-213. [CrossRef] [PubMed]
25. Kuhlmann, J.D.; Wimberger, P.; Wilsch, K.; Fluck, M.; Suter, L.; Brunner, G. Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients. Clin. Chem. Lab. Med. 2015, 53, 605-611. [CrossRef] [PubMed]
26. Bahn, J.H.; Zhang, Q.; Li, F.; Chan, T.M.; Lin, X.; Kim, Y.; Wong, D.T.; Xiao, X. The landscape of microRNA, Piwi-interacting RNA, and circular RNA in human saliva. Clin. Chem. 2015, 61, 221-230. [CrossRef] [PubMed]
27. Szabo, G.; Bala, S. MicroRNAs in liver disease. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 542-552. [CrossRef] [PubMed]
28. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297. [CrossRef]
29. Xu, L.; Qi, X.; Duan, S.; Xie, Y.; Ren, X.; Chen, G.; Yang, X.; Han, L.; Dong, Q. MicroRNAs: Potential biomarkers for disease diagnosis. Biomed. Mater. Eng. 2014, 24, 3917-3925. [PubMed]
30. Hayes, J.; Peruzzi, P.P.; Lawler, S. MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol. Med. 2014, 20, 460-469. [CrossRef] [PubMed]
31. Price, N.L.; Ramirez, C.M.; Fernandez-Hernando, C. Relevance of microRNA in metabolic diseases. Crit. Rev. Clin. Lab. Sci. 2014, 51, 305-320. [CrossRef] [PubMed]
32. Scian, M.J.; Maluf, D.G.; David, K.G.; Archer, K.J.; Suh, J.L.; Wolen, A.R.; Mba, M.U.; Massey, H.D.; King, A.L.; Gehr, T., et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am. J. Transplant. 2011, 11, 2110-2122. [CrossRef] [PubMed]
33. Shigehara, K.; Yokomuro, S.; Ishibashi, O.; Mizuguchi, Y.; Arima, Y.; Kawahigashi, Y.; Kanda, T.; Akagi, I.; Tajiri, T.; Yoshida, H., et al. Real-time PCR-based analysis of the human bile micrornaome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS ONE 2011, 6, e23584. [CrossRef] [PubMed]
34. Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56, 1733-1741. [CrossRef] [PubMed]
35. Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X., et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18, 997-1006. [CrossRef] [PubMed]
36. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518. [CrossRef] [PubMed]
37. Schwarzenbach, H.; Nishida, N.; Calin, G.A.; Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 2014, 11, 145-156. [CrossRef] [PubMed]
38. Arroyo, J.D.; Chevillet, J.R.; Kroh, E.M.; Ruf, I.K.; Pritchard, C.C.; Gibson, D.F.; Mitchell, P.S.; Bennett, C.F.; Pogosova-Agadjanyan, E.L.; Stirewalt, D.L., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA 2011, 108, 5003-5008. [CrossRef] [PubMed]
39. Vickers, K.C.; Palmisano, B.T.; Shoucri, B.M.; Shamburek, R.D.; Remaley, A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13, 423-433. [CrossRef] [PubMed]
40. Wang, K.; Zhang, S.; Weber, J.; Baxter, D.; Galas, D.J. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010, 38, 7248-7259. [CrossRef] [PubMed]
41. Hunter, M.P.; Ismail, N.; Zhang, X.; Aguda, B.D.; Lee, E.J.; Yu, L.; Xiao, T.; Schafer, J.; Lee, M.L.; Schmittgen, T.D., et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008, 3, e3694. [CrossRef] [PubMed]
42. Gilad, S.; Meiri, E.; Yogev, Y.; Benjamin, S.; Lebanony, D.; Yerushalmi, N.; Benjamin, H.; Kushnir, M.; Cholakh, H.; Melamed, N., et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008, 3, e3148. [CrossRef] [PubMed]
43. Turchinovich, A.; Weiz, L.; Langheinz, A.; Burwinkel, B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011, 39, 7223-7233. [CrossRef] [PubMed]
44. Li, L.; Zhu, D.; Huang, L.; Zhang, J.; Bian, Z.; Chen, X.; Liu, Y.; Zhang, C.Y.; Zen, K. Argonaute 2 complexes selectively protect the circulating microRNAs in cell-secreted microvesicles. PLoS ONE 2012, 7, e46957. [CrossRef] [PubMed]
45. Lemoinne, S.; Thabut, D.; Housset, C.; Moreau, R.; Valla, D.; Boulanger, C.M.; Rautou, P.E. The emerging roles of microvesicles in liver diseases. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 350-361. [CrossRef] [PubMed]
46. Arrese, M.; Eguchi, A.; Feldstein, A.E. Circulating microRNAs: Emerging biomarkers of liver disease. Semin. Liver Dis. 2015, 35, 43-54. [CrossRef] [PubMed]
47. Pirola, C.J.; Fernandez Gianotti, T.; Castano, G.O.; Mallardi, P.; San Martino, J.; Mora Gonzalez Lopez Ledesma, M.; Flichman, D.; Mirshahi, F.; Sanyal, A.J.; Sookoian, S. Circulating microRNA signature in non-alcoholic fatty liver disease: From serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015, 64, 800-812. [CrossRef] [PubMed]
48. Povero, D.; Eguchi, A.; Li, H.; Johnson, C.D.; Papouchado, B.G.; Wree, A.; Messer, K.; Feldstein, A.E. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS ONE 2014, 9, e113651. [CrossRef] [PubMed]
49. Bala, S.; Petrasek, J.; Mundkur, S.; Catalano, D.; Levin, I.; Ward, J.; Alao, H.; Kodys, K.; Szabo, G. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012, 56, 1946-1957. [CrossRef] [PubMed]
50. Masyuk, A.I.; Masyuk, T.V.; Larusso, N.F. Exosomes in the pathogenesis, diagnostics and therapeutics of liver diseases. J. Hepatol. 2013, 59, 621-625. [CrossRef] [PubMed]
51. Valadi, H.; Ekstrom, K.; Bossios, A.; Sjostrand, M.; Lee, J.J.; Lotvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654-659. [CrossRef] [PubMed]
52. Fabbri, M.; Paone, A.; Calore, F.; Galli, R.; Gaudio, E.; Santhanam, R.; Lovat, F.; Fadda, P.; Mao, C.; Nuovo, G.J., et al. MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA 2012, 109, E2110-E2116. [CrossRef] [PubMed]
53. Murakami, Y.; Toyoda, H.; Tanahashi, T.; Tanaka, J.; Kumada, T.; Yoshioka, Y.; Kosaka, N.; Ochiya, T.; Taguchi, Y.H. Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease. PLoS ONE 2012, 7, e48366. [CrossRef] [PubMed]
54. Kornek, M.; Popov, Y.; Libermann, T.A.; Afdhal, N.H.; Schuppan, D. Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology 2011, 53, 230-242. [CrossRef] [PubMed]
55. Deregibus, M.C.; Cantaluppi, V.; Calogero, R.; Lo Iacono, M.; Tetta, C.; Biancone, L.; Bruno, S.; Bussolati, B.; Camussi, G. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007, 110, 2440-2448. [CrossRef] [PubMed]
56. Zhang, J.; Li, S.; Li, L.; Li, M.; Guo, C.; Yao, J.; Mi, S. Exosome and exosomal microRNA: Trafficking, sorting, and function. Genom. Proteom. Bioinform. 2015, 13, 17-24. [CrossRef] [PubMed]
57. Kroh, E.M.; Parkin, R.K.; Mitchell, P.S.; Tewari, M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50, 298-301. [CrossRef] [PubMed]
58. Li, Y.; Kowdley, K.V. Method for microRNA isolation from clinical serum samples. Anal. Biochem. 2012, 431, 69-75. [CrossRef] [PubMed]
59. Monleau, M.; Bonnel, S.; Gostan, T.; Blanchard, D.; Courgnaud, V.; Lecellier, C.H. Comparison of different extraction techniques to profile microRNAs from human sera and peripheral blood mononuclear cells. BMC Genom. 2014, 15, 395. [CrossRef] [PubMed]
60. Jarry, J.; Schadendorf, D.; Greenwood, C.; Spatz, A.; van Kempen, L.C. The validity of circulating microRNAs in oncology: Five years of challenges and contradictions. Mol. Oncol. 2014, 8, 819-829. [CrossRef] [PubMed]
61. Pritchard, C.C.; Cheng, H.H.; Tewari, M. MicroRNA profiling: Approaches and considerations. Nat. Rev. Genet. 2012, 13, 358-369. [CrossRef] [PubMed]
62. Ono, S.; Lam, S.; Nagahara, M.; Hoon, D.S. Circulating microRNA biomarkers as liquid biopsy for cancer patients: Pros and cons of current assays. J. Clin. Med. 2015, 4, 1890-1907. [CrossRef] [PubMed]
63. Moldovan, L.; Batte, K.E.; Trgovcich, J.; Wisler, J.; Marsh, C.B.; Piper, M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J. Cell Mol. Med. 2014, 18, 371-390. [CrossRef] [PubMed]
64. De Planell-Saguer, M.; Rodicio, M.C. Analytical aspects of microRNA in diagnostics: A review. Anal. Chim. Acta 2011, 699, 134-152. [CrossRef] [PubMed]
65. Chen, C.; Ridzon, D.A.; Broomer, A.J.; Zhou, Z.; Lee, D.H.; Nguyen, J.T.; Barbisin, M.; Xu, N.L.; Mahuvakar, V.R.; Andersen, M.R., et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005, 33, e179. [CrossRef] [PubMed]
66. Kang, K.; Peng, X.; Luo, J.; Gou, D. Identification of circulating miRNA biomarkers based on global quantitative real-time PCR profiling. J. Anim. Sci. Biotechnol. 2012, 3, 4. [CrossRef] [PubMed]
67. Jensen, S.G.; Lamy, P.; Rasmussen, M.H.; Ostenfeld, M.S.; Dyrskjot, L.; Orntoft, T.F.; Andersen, C.L. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genom. 2011, 12, 435. [CrossRef] [PubMed]
68. Wang, W.T.; Chen, Y.Q. Circulating miRNAs in cancer: From detection to therapy. J. Hematol. Oncol. 2014, 7, 86. [CrossRef] [PubMed]
69. Michelotti, G.A.; Machado, M.V.; Diehl, A.M. Nafld, nash and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 656-665. [CrossRef] [PubMed]
70. Esau, C.; Davis, S.; Murray, S.F.; Yu, X.X.; Pandey, S.K.; Pear, M.; Watts, L.; Booten, S.L.; Graham, M.; McKay, R., et al. MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3, 87-98. [CrossRef] [PubMed]
71. Cheung, O.; Puri, P.; Eicken, C.; Contos, M.J.; Mirshahi, F.; Maher, J.W.; Kellum, J.M.; Min, H.; Luketic, V.A.; Sanyal, A.J. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008, 48, 1810-1820. [CrossRef] [PubMed]
72. Cermelli, S.; Ruggieri, A.; Marrero, J.A.; Ioannou, G.N.; Beretta, L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 2011, 6, e23937. [CrossRef] [PubMed]
73. Yamada, H.; Suzuki, K.; Ichino, N.; Ando, Y.; Sawada, A.; Osakabe, K.; Sugimoto, K.; Ohashi, K.; Teradaira, R.; Inoue, T., et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin. Chim. Acta 2013, 424, 99-103. [CrossRef] [PubMed]
74. Yamada, H.; Ohashi, K.; Suzuki, K.; Munetsuna, E.; Ando, Y.; Yamazaki, M.; Ishikawa, H.; Ichino, N.; Teradaira, R.; Hashimoto, S. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin. Chim. Acta 2015, 446, 267-271. [CrossRef] [PubMed]
75. Tryndyak, V.P.; Latendresse, J.R.; Montgomery, B.; Ross, S.A.; Beland, F.A.; Rusyn, I.; Pogribny, I.P. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline-and folate-deficient diet. Toxicol. Appl. Pharmacol. 2012, 262, 52-59. [CrossRef] [PubMed]
76. Wang, B.; Majumder, S.; Nuovo, G.; Kutay, H.; Volinia, S.; Patel, T.; Schmittgen, T.D.; Croce, C.; Ghoshal, K.; Jacob, S.T. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009, 50, 1152-1161. [CrossRef] [PubMed]
77. Pogribny, I.P.; Starlard-Davenport, A.; Tryndyak, V.P.; Han, T.; Ross, S.A.; Rusyn, I.; Beland, F.A. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab. Investig. 2010, 90, 1437-1446. [CrossRef] [PubMed]
78. Wang, R.; Hong, J.; Cao, Y.; Shi, J.; Gu, W.; Ning, G.; Zhang, Y.; Wang, W. Elevated circulating microRNA-122 is associated with obesity and insulin resistance in young adults. Eur. J. Endocrinol. 2015, 172, 291-300. [CrossRef] [PubMed]
79. Tan, Y.; Ge, G.; Pan, T.; Wen, D.; Gan, J. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS ONE 2014, 9, e105192. [CrossRef] [PubMed]
80. Qi, P.; Cheng, S.Q.; Wang, H.; Li, N.; Chen, Y.F.; Gao, C.F. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS ONE 2011, 6, e28486. [CrossRef] [PubMed]
81. Xu, J.; Wu, C.; Che, X.; Wang, L.; Yu, D.; Zhang, T.; Huang, L.; Li, H.; Tan, W.; Wang, C., et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog. 2011, 50, 136-142. [CrossRef] [PubMed]
82. El-Garem, H.; Ammer, A.; Shehab, H.; Shaker, O.; Anwer, M.; El-Akel, W.; Omar, H. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J. Hepatol. 2014, 6, 818-824. [CrossRef] [PubMed]
83. Hung, C.H.; Hu, T.H.; Lu, S.N.; Kuo, F.Y.; Chen, C.H.; Wang, J.H.; Huang, C.M.; Lee, C.M.; Lin, C.Y.; Yen, Y.H., et al. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. Int. J. Cancer 2015, 138, 714-720. [CrossRef] [PubMed]
84. Wang, H.; Hou, L.; Li, A.; Duan, Y.; Gao, H.; Song, X. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed. Res. Int. 2014, 2014, 864894. [CrossRef] [PubMed]
85. Sun, C.; Huang, F.; Liu, X.; Xiao, X.; Yang, M.; Hu, G.; Liu, H.; Liao, L. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int. J. Mol. Med. 2015, 35, 847-853. [CrossRef] [PubMed]
86. Sukata, T.; Sumida, K.; Kushida, M.; Ogata, K.; Miyata, K.; Yabushita, S.; Uwagawa, S. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol. Lett. 2011, 200, 46-52. [CrossRef] [PubMed]
87. Ge, W.; Yu, D.C.; Li, Q.G.; Chen, X.; Zhang, C.Y.; Ding, Y.T. Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances. Clin. Lab. 2014, 60, 427-434. [PubMed]
88. Qu, K.Z.; Zhang, K.; Li, H.; Afdhal, N.H.; Albitar, M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J. Clin. Gastroenterol. 2011, 45, 355-360. [CrossRef] [PubMed]
89. El-Abd, N.E.; Fawzy, N.A.; El-Sheikh, S.M.; Soliman, M.E. Circulating miRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early detection of hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection. Mol. Diagn. Ther. 2015, 19, 213-220. [CrossRef] [PubMed]
90. Tan, Y.; Ge, G.; Pan, T.; Wen, D.; Chen, L.; Yu, X.; Zhou, X.; Gan, J. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS ONE 2014, 9, e107986. [CrossRef] [PubMed]
91. Motawi, T.K.; Shaker, O.G.; El-Maraghy, S.A.; Senousy, M.A. Serum microRNAs as potential biomarkers for early diagnosis of hepatitis C virus-related hepatocellular carcinoma in Egyptian patients. PLoS ONE 2015, 10, e0137706. [CrossRef] [PubMed]
92. Wen, Y.; Han, J.; Chen, J.; Dong, J.; Xia, Y.; Liu, J.; Jiang, Y.; Dai, J.; Lu, J.; Jin, G., et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int. J. Cancer 2015, 137, 1679-1690. [CrossRef] [PubMed]
93. Celikbilek, M.; Baskol, M.; Taheri, S.; Deniz, K.; Dogan, S.; Zararsiz, G.; Gursoy, S.; Guven, K.; Ozbakir, O.; Dundar, M., et al. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J. Hepatol 2014, 6, 613-620. [PubMed]
94. Jiang, L.; Cheng, Q.; Zhang, B.H.; Zhang, M.Z. Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: A validation set from China. Medicine (Baltimore) 2015, 94, e603. [CrossRef] [PubMed]
95. Zhang, Y.; Cheng, X.; Lu, Z.; Wang, J.; Chen, H.; Fan, W.; Gao, X.; Lu, D. Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease. Diabetes Res. Clin. Pract. 2013, 99, 327-334. [CrossRef] [PubMed]
96. Liu, A.M.; Yao, T.J.; Wang, W.; Wong, K.F.; Lee, N.P.; Fan, S.T.; Poon, R.T.; Gao, C.; Luk, J.M. Circulating miR-15b andmiR-130b in serumas potentialmarkers for detecting hepatocellular carcinoma: A retrospective cohort study. BMJ Open 2012, 2, e000825. [CrossRef] [PubMed]
97. Hsieh, C.H.; Rau, C.S.; Wu, S.C.; Yang, J.C.; Wu, Y.C.; Lu, T.H.; Tzeng, S.L.; Wu, C.J.; Lin, C.W. Weight-reduction through a low-fat diet causes differential expression of circulating microRNAs in obese C57BL/6 mice. BMC Genom. 2015, 16, 699. [CrossRef] [PubMed]
98. Chen, Y.; Chen, J.; Liu, Y.; Li, S.; Huang, P. Plasma miR-15b-5p, miR-338-5p, and miR-764 as biomarkers for hepatocellular carcinoma. Med. Sci. Monit. 2015, 21, 1864-1871. [CrossRef] [PubMed]
99. Simionescu, N.; Niculescu, L.S.; Sanda, G.M.; Margina, D.; Sima, A.V. Analysis of circulating microRNAs that are specifically increased in hyperlipidemic and/or hyperglycemic sera. Mol. Biol. Rep. 2014, 41, 5765-5773. [CrossRef] [PubMed]
100. Huang, C.F.; Sun, C.C.; Zhao, F.; Zhang, Y.D.; Li, D.J. miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis. J. Gastroenterol. 2015, 50, 480-490. [CrossRef] [PubMed]
101. Halasz, T.; Horvath, G.; Par, G.; Werling, K.; Kiss, A.; Schaff, Z.; Lendvai, G. miR-122 negatively correlates with liver fibrosis as detected by histology and fibroscan. World J. Gastroenterol. 2015, 21, 7814-7823. [CrossRef] [PubMed]
102. Zeng, C.; Wang, R.; Li, D.; Lin, X.J.; Wei, Q.K.; Yuan, Y.; Wang, Q.; Chen, W.; Zhuang, S.M. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 2010, 52, 1702-1712. [CrossRef] [PubMed]
103. Coulouarn, C.; Factor, V.M.; Andersen, J.B.; Durkin, M.E.; Thorgeirsson, S.S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28, 3526-3536. [CrossRef] [PubMed]
104. Hsu, S.H.; Wang, B.; Kota, J.; Yu, J.; Costinean, S.; Kutay, H.; Yu, L.; Bai, S.; La Perle, K.; Chivukula, R.R., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Investig. 2012, 122, 2871-2883. [CrossRef] [PubMed]
105. Tsai, W.C.; Hsu, S.D.; Hsu, C.S.; Lai, T.C.; Chen, S.J.; Shen, R.; Huang, Y.; Chen, H.C.; Lee, C.H.; Tsai, T.F., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Investig. 2012, 122, 2884-2897. [CrossRef] [PubMed]
106. Takaki, Y.; Saito, Y.; Takasugi, A.; Toshimitsu, K.; Yamada, S.; Muramatsu, T.; Kimura, M.; Sugiyama, K.; Suzuki, H.; Arai, E., et al. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis. Cancer Sci. 2014, 105, 1254-1260. [CrossRef] [PubMed]
107. Zhang, Y.; Jia, Y.; Zheng, R.; Guo, Y.; Wang, Y.; Guo, H.; Fei, M.; Sun, S. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin. Chem. 2010, 56, 1830-1838. [CrossRef] [PubMed]
108. Xu, Y.; Bu, X.; Dai, C.; Shang, C. High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients. Tumour Biol. 2015, 36, 4773-4776. [CrossRef] [PubMed]
109. Rodrigues, P.M.; Afonso, M.B.; Simão, A.L.; Caridade, M.; Carvalho, C.C.; Trindade, A.; Duarte, A.; Borralho, P.M.; Machado, M.V.; Cortez-Pinto, H., et al. miR-21 inhibition and FXR activation synergistically ameilorate disease pathogenesis in a mouse model of NAFLD. J. Hepatol. 2015, 62, S704. [CrossRef]
110. Wu, H.; Ng, R.; Chen, X.; Steer, C.J.; Song, G. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut 2015. [CrossRef]
111. Tomimaru, Y.; Eguchi, H.; Nagano, H.; Wada, H.; Kobayashi, S.; Marubashi, S.; Tanemura, M.; Tomokuni, A.; Takemasa, I.; Umeshita, K., et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J. Hepatol. 2012, 56, 167-175. [CrossRef] [PubMed]
112. Li, B.S.; Zhao, Y.L.; Guo, G.; Li, W.; Zhu, E.D.; Luo, X.; Mao, X.H.; Zou, Q.M.; Yu, P.W.; Zuo, Q.F., et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS ONE 2012, 7, e41629. [CrossRef] [PubMed]
113. Shan, L.; Ji, Q.; Cheng, G.; Xia, J.; Liu, D.; Wu, C.; Zhu, B.; Ding, Y. Diagnostic value of circulating miR-21 for colorectal cancer: A meta-analysis. Cancer Biomark. 2015, 15, 47-56. [PubMed]
114. Liao, Q.; Han, P.; Huang, Y.; Wu, Z.; Chen, Q.; Li, S.; Ye, J.; Wu, X. Potential role of circulating microRNA-21 for hepatocellular carcinoma diagnosis: A meta-analysis. PLoS ONE 2015, 10, e0130677. [CrossRef] [PubMed]
115. Ferreira, D.M.; Castro, R.E.; Machado, M.V.; Evangelista, T.; Silvestre, A.; Costa, A.; Coutinho, J.; Carepa, F.; Cortez-Pinto, H.; Rodrigues, C.M. Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. Diabetologia 2011, 54, 1788-1798. [CrossRef] [PubMed]
116. Afonso, M.B.; Rodrigues, P.M.; Carvalho, T.; Caridade, M.; Borralho, P.; Cortez-Pinto, H.; Castro, R.E.; Rodrigues, C.M. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. Clin. Sci. (Lond.) 2015, 129, 721-739. [CrossRef] [PubMed]
117. Ferreira, D.M.; Simao, A.L.; Rodrigues, C.M.; Castro, R.E. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. FEBS J. 2014, 281, 2503-2524. [CrossRef] [PubMed]
118. Castro, R.E.; Ferreira, D.M.; Afonso, M.B.; Borralho, P.M.; Machado, M.V.; Cortez-Pinto, H.; Rodrigues, C.M. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J. Hepatol. 2013, 58, 119-125. [CrossRef] [PubMed]
119. Dang, Y.; Luo, D.; Rong, M.; Chen, G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS ONE 2013, 8, e61054. [CrossRef] [PubMed]
120. Budhu, A.; Jia, H.L.; Forgues, M.; Liu, C.G.; Goldstein, D.; Lam, A.; Zanetti, K.A.; Ye, Q.H.; Qin, L.X.; Croce, C.M., et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47, 897-907. [CrossRef] [PubMed]
121. Sharma, H.; Estep, M.; Birerdinc, A.; Afendy, A.; Moazzez, A.; Elariny, H.; Goodman, Z.; Chandhoke, V.; Baranova, A.; Younossi, Z.M. Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2013, 28, 1410-1415. [CrossRef] [PubMed]
122. Liu, A.M.; Poon, R.T.; Luk, J.M. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem. Biophys. Res. Commun. 2010, 394, 623-627. [CrossRef] [PubMed]
123. He, X.X.; Chang, Y.; Meng, F.Y.; Wang, M.Y.; Xie, Q.H.; Tang, F.; Li, P.Y.; Song, Y.H.; Lin, J.S. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene 2012, 31, 3357-3369. [CrossRef] [PubMed]
124. Yoo, B.K.; Emdad, L.; Su, Z.Z.; Villanueva, A.; Chiang, D.Y.; Mukhopadhyay, N.D.; Mills, A.S.; Waxman, S.; Fisher, R.A.; Llovet, J.M., et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J. Clin. Investig. 2009, 119, 465-477. [CrossRef] [PubMed]
125. Li, L.M.; Hu, Z.B.; Zhou, Z.X.; Chen, X.; Liu, F.Y.; Zhang, J.F.; Shen, H.B.; Zhang, C.Y.; Zen, K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010, 70, 9798-9807. [CrossRef] [PubMed]
126. Yang, Z.; Miao, R.; Li, G.; Wu, Y.; Robson, S.C.; Yang, X.; Zhao, Y.; Zhao, H.; Zhong, Y. Identification of recurrence related microRNAs in hepatocellular carcinoma after surgical resection. Int J. Mol. Sci. 2013, 14, 1105-1118. [CrossRef] [PubMed]
127. Tan, Y.; Lin, B.; Ye, Y.; Wen, D.; Chen, L.; Zhou, X. Differential expression of serum microRNAs in cirrhosis that evolve into hepatocellular carcinoma related to hepatitis B virus. Oncol. Rep. 2015, 33, 2863-2870. [PubMed]
128. Zheng, L.; Lv, G.C.; Sheng, J.; Yang, Y.D. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J. Gastroenterol. Hepatol. 2010, 25, 156-163. [CrossRef] [PubMed]
129. Liao, C.G.; Kong, L.M.; Zhou, P.; Yang, X.L.; Huang, J.G.; Zhang, H.L.; Lu, N. miR-10b is overexpressed in hepatocellular carcinoma and promotes cell proliferation, migration and invasion through RhoC, uPAR and MMPS. J. Transl. Med. 2014, 12, 234. [CrossRef] [PubMed]
130. Miller, A.M.; Gilchrist, D.S.; Nijjar, J.; Araldi, E.; Ramirez, C.M.; Lavery, C.A.; Fernandez-Hernando, C.; McInnes, I.B.; Kurowska-Stolarska, M. miR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS ONE 2013, 8, e72324. [CrossRef]
131. Lin, X.; Jia, J.; Du, T.; Li, W.; Wang, X.; Wei, J.; Lin, X.; Zeng, H.; Yao, L.; Chen, X., et al. Overexpression ofmiR-155 in the liver of transgenic mice alters the expression profiling of hepatic genes associated with lipid metabolism. PLoS ONE 2015, 10, e0118417. [CrossRef] [PubMed]
132. Bala, S.; Tilahun, Y.; Taha, O.; Alao, H.; Kodys, K.; Catalano, D.; Szabo, G. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J. Transl. Med. 2012, 10, 151. [CrossRef] [PubMed]
133. Yan, X.L.; Jia, Y.L.; Chen, L.; Zeng, Q.; Zhou, J.N.; Fu, C.J.; Chen, H.X.; Yuan, H.F.; Li, Z.W.; Shi, L., et al. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: Role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology 2013, 57, 2274-2286. [CrossRef] [PubMed]
134. Bala, S.; Csak, T.; Momen-Heravi, F.; Lippai, D.; Kodys, K.; Catalano, D.; Satishchandran, A.; Ambros, V.; Szabo, G. Biodistribution and function of extracellular miRNA-155 in mice. Sci. Rep. 2015, 5, 10721. [CrossRef] [PubMed]
135. Zhou, B.; Li, C.; Qi, W.; Zhang, Y.; Zhang, F.; Wu, J.X.; Hu, Y.N.; Wu, D.M.; Liu, Y.; Yan, T.T., et al. Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia 2012, 55, 2032-2043. [CrossRef] [PubMed]
136. Wang, B.; Li, W.; Guo, K.; Xiao, Y.; Wang, Y.; Fan, J. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem. Biophys. Res. Commun. 2012, 421, 4-8. [CrossRef] [PubMed]
137. Brockhausen, J.; Tay, S.S.; Grzelak, C.A.; Bertolino, P.; Bowen, D.G.; d’Avigdor, W.M.; Teoh, N.; Pok, S.; Shackel, N.; Gamble, J.R., et al. miR-181a mediates TGF-beta-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer. Liver Int. 2015, 35, 240-253. [CrossRef] [PubMed]
138. Zou, C.; Li, Y.; Cao, Y.; Zhang, J.; Jiang, J.; Sheng, Y.; Wang, S.; Huang, A.; Tang, H. Up-regulatedmicroRNA-181a induces carcinogenesis in hepatitis B virus-related hepatocellular carcinoma by targeting E2F5. BMC Cancer 2014, 14, 97. [CrossRef] [PubMed]
139. Yang, W.M.; Jeong, H.J.; Park, S.W.; Lee, W. Obesity-induced miR-15b is linked causally to the development of insulin resistance through the repression of the insulin receptor in hepatocytes. Mol. Nutr. Food Res. 2015, 59, 2303-2314. [CrossRef] [PubMed]
140. Chung, G.E.; Yoon, J.H.; Myung, S.J.; Lee, J.H.; Lee, S.H.; Lee, S.M.; Kim, S.J.; Hwang, S.Y.; Lee, H.S.; Kim, C.Y. High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma. Oncol. Rep. 2010, 23, 113-119.[PubMed]
141. Yang, Y.; Hou, N.; Wang, X.; Wang, L.; Chang, S.; He, K.; Zhao, Z.; Zhao, X.; Song, T.; Huang, C. miR-15b-5p induces endoplasmic reticulum stress and apoptosis in human hepatocellular carcinoma, both in vitro and in vivo, by suppressing RAB1A. Oncotarget 2015, 6, 16227-16238. [CrossRef] [PubMed]
142. Rayner, K.J.; Esau, C.C.; Hussain, F.N.; McDaniel, A.L.; Marshall, S.M.; van Gils, J.M.; Ray, T.D.; Sheedy, F.J.; Goedeke, L.; Liu, X., et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011, 478, 404-407. [CrossRef] [PubMed]
143. Baselga-Escudero, L.; Pascual-Serrano, A.; Ribas-Latre, A.; Casanova, E.; Salvado, M.J.; Arola, L.; Arola-Arnal, A.; Blade, C. Long-term supplementation with a low dose of proanthocyanidins normalized liver miR-33a and miR-122 levels in high-fat diet-induced obese rats. Nutr. Res. 2015, 35, 337-345. [CrossRef] [PubMed]
144. Li, Z.J.; Ou-Yang, P.H.; Han, X.P. Profibrotic effect of miR-33a with AKT activation in hepatic stellate cells. Cell. Signal. 2014, 26, 141-148. [CrossRef] [PubMed]
145. Zhou, J.; Yu, L.; Gao, X.; Hu, J.; Wang, J.; Dai, Z.; Wang, J.F.; Zhang, Z.; Lu, S.; Huang, X., et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J. Clin. Oncol. 2011, 29, 4781-4788. [CrossRef] [PubMed]
146. Liu, W.H.; Ren, L.N.; Wang, X.; Wang, T.; Zhang, N.; Gao, Y.; Luo, H.; Navarro-Alvarez, N.; Tang, L.J. Combination of exosomes and circulatingmicroRNAsmay serve as a promising tumormarker complementary to alpha-fetoprotein for early-stage hepatocellular carcinoma diagnosis in rats. J. Cancer Res. Clin. Oncol. 2015, 141, 1767-1778. [CrossRef] [PubMed]
147. Sugimachi, K.; Matsumura, T.; Hirata, H.; Uchi, R.; Ueda, M.; Ueo, H.; Shinden, Y.; Iguchi, T.; Eguchi, H.; Shirabe, K., et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br. J. Cancer 2015, 112, 532-538. [CrossRef] [PubMed]
148. Lafaro, K.J.; Demirjian, A.N.; Pawlik, T.M. Epidemiology of hepatocellular carcinoma. Surg. Oncol. Clin. N. Am. 2015, 24, 1-17. [CrossRef] [PubMed]